tradingkey.logo
tradingkey.logo
Pesquisar

Cardio Diagnostics Holdings Inc

CDIO
Adicionar à lista de desejos
1.990USD
-0.120-5.69%
Fechamento 07/02, 13:00ETCotações atrasadas em 15 min
3.52MValor de mercado
0.08P/L TTM

Mais detalhes de Cardio Diagnostics Holdings Inc Empresa

Cardio Diagnostics Holdings, Inc. is an artificial intelligence-powered precision cardiovascular medicine company. The Company develops and commercializes a series of products for various types of cardiovascular disease and associated co-morbidities, including coronary heart disease (CHD), stroke, heart failure and diabetes, by leveraging its artificial intelligence (AI)-driven Integrated Genetic-Epigenetic Engine. Its first product, Epi+Gen CHD, is an epigenetics-based clinical blood test capable of assessing near-term (three-year) risk for CHD, and its second product, PrecisionCHD, is an epigenetics-based clinical blood test for the detection of CHD. CardioInnovate360 is a research use only (RUO) solution to support the discovery, development, and validation of biopharmaceuticals for the assessment and management of cardiovascular diseases. HeartRisk is a cardiovascular risk intelligence platform that combines insights from anonymized and aggregated clinical cardiovascular data.

Informações de Cardio Diagnostics Holdings Inc

Código da empresaCDIO
Nome da EmpresaCardio Diagnostics Holdings Inc
Data de listagemNov 23, 2021
CEODogan (Meeshanthini V)
Número de funcionários13
Tipo de títulosOrdinary Share
Fim do ano fiscalNov 23
Endereço311 W. Superior Street
CidadeCHICAGO
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal60645
Telefone18552269991
Site
Código da empresaCDIO
Data de listagemNov 23, 2021
CEODogan (Meeshanthini V)

Executivos da empresa Cardio Diagnostics Holdings Inc

Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Timur Dogan, Ph.D.
Mr. Timur Dogan, Ph.D.
Chief Technology Officer
Chief Technology Officer
107.26K
+96.01%
Dr. Warren Hosseinion, M.D.
Dr. Warren Hosseinion, M.D.
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
3.87K
--
Dr. Robert Philibert, M.D., Ph.D.
Dr. Robert Philibert, M.D., Ph.D.
Chief Medical Officer, Director
Chief Medical Officer, Director
3.25K
--
Mr. James Intrater
Mr. James Intrater
Independent Director
Independent Director
2.39K
--
Dr. Meeshanthini V. (Meesha) Dogan, Ph.D.
Dr. Meeshanthini V. (Meesha) Dogan, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Ms. Elisa Luqman, Esq., J.D.
Ms. Elisa Luqman, Esq., J.D.
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Paul F. Burton, J.D.
Mr. Paul F. Burton, J.D.
Independent Director
Independent Director
--
--
Ms. Wendy J. Betts
Ms. Wendy J. Betts
Independent Director
Independent Director
--
--
Mr. Peter K. Fung
Mr. Peter K. Fung
Independent Director
Independent Director
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Timur Dogan, Ph.D.
Mr. Timur Dogan, Ph.D.
Chief Technology Officer
Chief Technology Officer
107.26K
+96.01%
Dr. Warren Hosseinion, M.D.
Dr. Warren Hosseinion, M.D.
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
3.87K
--
Dr. Robert Philibert, M.D., Ph.D.
Dr. Robert Philibert, M.D., Ph.D.
Chief Medical Officer, Director
Chief Medical Officer, Director
3.25K
--
Mr. James Intrater
Mr. James Intrater
Independent Director
Independent Director
2.39K
--
Dr. Meeshanthini V. (Meesha) Dogan, Ph.D.
Dr. Meeshanthini V. (Meesha) Dogan, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Ms. Elisa Luqman, Esq., J.D.
Ms. Elisa Luqman, Esq., J.D.
Chief Financial Officer
Chief Financial Officer
--
--

Perguntas frequentes

Quem são os cinco principais acionistas de Cardio Diagnostics Holdings Inc?

Os cinco principais acionistas de Cardio Diagnostics Holdings Inc são: Mr. Timur Dogan, Ph.D.

Quantas instituições possuem ações da Cardio Diagnostics Holdings Inc (CDIO)?

Em 2026Q1, 38 instituições possuíam ações da Cardio Diagnostics Holdings Inc, com valor de mercado aproximado de 138.49K, representando 4.68% do total de ações. Em comparação com 2025Q4, a participação institucional aumentou em -23968.00.